Bartelink H
Netherlands Cancer Institute - Antoni van Leeuwenhoek Ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Breast. 2007 Dec;16 Suppl 2:S84-8. doi: 10.1016/j.breast.2007.07.010. Epub 2007 Aug 24.
The rapid increase in the use of both radiotherapy and systemic therapy for patients with early breast cancer requires reconsideration of the strategies that have been used in the past for combining both treatments. In these considerations the impact of both radiotherapy as well as systemic therapy on local control and survival of breast cancer have to be considered. An important point for discussion has often been the sequencing of radiotherapy and systemic treatment. Nowadays the possibilities of trastuzumab for her-2 neu positive breast cancer leads to the question whether or not this can be combined with radiotherapy. Finally new possibilities of sophisticated radiotherapy approaches allow further minimizing the late toxicity of radiotherapy.
早期乳腺癌患者放疗和全身治疗的使用迅速增加，这就需要重新考虑过去用于联合这两种治疗方法的策略。在这些考量中，必须兼顾放疗和全身治疗对乳腺癌局部控制和生存的影响。放疗和全身治疗的先后顺序常常是一个重要的讨论点。如今，针对人表皮生长因子受体2（HER-2）阳性乳腺癌的曲妥珠单抗治疗带来了一个问题，即它能否与放疗联合使用。最后，先进放疗方法的新可能性使放疗的晚期毒性得以进一步降低。
